Government has targeted prices of 56 important drugs which are used to control cancer, diabetes, viral infections and supreme. The average price will decline by 25 per cent. Although the drug price regulator National Pharmaceutical Pricing Authority (NPPA) such as glucose and sodium chloride injection of small amounts of intravenous fluid packs given prices have increased.
NPPA's new price range of the companies have come into the sphere of medicine pricing are the Abbott Healthcare, Cipla, Lupin, Elenmbik, Elkem Labotryj, Novartis, Biocon, Intas Pharmaceuticals, Hetero Healthcare and former Ranbaxy (now Sun pharmaceuticals industries too included).Authority chairperson Bhupendra Singh conveyed that the prices of drug have been decline by an average 25 per cent. Cut 10 to 15 percent in some cases while in other cases it is 45 to 50 percent. In addition of IV fluid pack, 31 in the case of small quantities of scheduled formulations are increased prices, while prices have been cut to pack large amounts.
NPPA conveyed in its notification that those manufacturers who do not comply with the higher price range, they will have to raise additional funds deposited with interest. According to the announcement, the Authority Drugs (Prices Control) Amendment Order 2016, under Schedule 1 of the 56 scheduled formulations price and the retail price fixed eight formulations are modified. Companies in the price of these drugs will be allowed to increase by 10 percent in a year.